尿管ステント市場：製品別、材料別、用途別、エンドユーザー別、地域別、2026-2032年

尿管ステント市場の評価、2026-2032年

泌尿器科疾患、特に腎臓結石の頻度上昇と、患者の回復と快適性を向上させる低侵襲技術の使用が、尿管ステント市場を前進させています。Verified Market Researchのアナリストによると、尿管ステント市場は、2024年には約5億4,854万米ドルの評価を下回り、予測期間中に8億4,374万米ドルの評価に達すると推定されています。

ステント材料や設計の技術的改善、特に柔軟で生体適合性の高い選択肢が市場の需要を押し上げています。これにより、市場は2026年から2032年にかけてCAGR 6.1％で成長します。

尿管ステント市場定義/概要

尿管ステントは、特に正常な尿の流れが阻害されている場合に、腎臓から膀胱への尿の排出を補助するために尿管に挿入される細く柔軟なチューブです。これらのステントは、腎結石、腫瘍や狭窄による尿管閉塞、腫脹や組織修復による術後の閉塞の治療に広く使用されています。尿管ステントは尿管の開通を維持し、最適な腎機能を確保すると同時に、尿路閉塞に伴う症状を緩和するため、泌尿器科治療における重要な要素です。

尿管ステント市場の需要を急増させる要因とは？

腎臓結石の発生増加は、尿管ステント市場の主な促進要因です。米国糖尿病・消化器・腎臓病研究所（NIDDK）は、腎臓結石は米国では男性の約11%、女性の約9%が罹患していると推定しています。NIDDKはまた、米国における腎結石の発生率は1970年代後半の3.8％から2000年代後半には8.8％に上昇したと指摘しています。このような有病率の増加は、より多くの尿管ステント手術を必要とし、市場拡大の原動力となっています。

高齢者は泌尿器系の問題を起こしやすいため、世界の高齢化が尿管ステントの需要を押し上げています。世界保健機関（WHO）は、2030年までに6人に1人が60歳以上になると予測しています。この数は2050年には5人に1人になると予測されています。統計上は、2020年の10億人から2030年には14億人、2050年には21億人に増加することになります。高齢者層は尿管ステントを必要とする疾患にかかりやすく、市場拡大に拍車をかけています。

さらに、尿管ステントの設計と材料の継続的な進歩は、患者の転帰を改善しながらその用途を広げています。例えば、米国食品医薬品局（FDA）は新しい尿管ステント技術を積極的に承認しています。腎臓から結石片を排出するためのニュートンドレーナー尿管カテーテルは、2019年にFDAによってブレークスルーデバイスに指定されました。こうした改良が尿管ステントの用途を拡大し、市場拡大の原動力となっています。FDAのデバイス・放射線衛生センター（CDRH）によると、革新的デバイスの承認数は2009年から2019年の間に25％増加しており、医療機器、特に尿管ステントの革新の傾向を示しています。

尿管ステント市場の成長を阻害する要因は？

薬剤溶出性ステントや生分解性ステントは、より良い転帰をもたらす可能性を秘めた画期的な技術の一例ですが、高価であるため、特に資源の乏しい地域では、患者やヘルスケア専門家の手が届きません。このような経済的負担は、これらの高度な解決策を採用する意欲を失わせ、結果として、同じ利点をもたらさないより安価な代替品に頼ることになります。

尿管ステント留置後に問題が発生するリスクは、もうひとつの難題です。患者はステントの移動、包埋、尿路感染などの合併症を発症し、余分な治療を必要とします。このような結果は患者の転帰に影響を与えるだけでなく、ヘルスケア支出と資源の使用量を増加させるため、医師はステント留置を第一選択の治療法として提案することを躊躇しています。

目次

第1章 尿管ステントの世界市場導入

• 市場の導入
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• バリデーション
• 一次資料
• データソース一覧

第4章 尿管ステントの世界市場展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 尿管ステントの世界市場、製品別

• 概要
• オープンエンドステント
• ダブルJステント
• クローズドエンドステント
• マルチループステント

第6章 尿管ステントの世界市場、材料別

• 概要
• 金属製ステント
• ポリマー製ステント

第7章 尿管ステントの世界市場：用途別

• 概要
• 腎臓結石
• 腎移植
• 腫瘍
• 尿失禁
• その他

第8章 尿管ステントの世界市場：エンドユーザー別

• 概要
• 病院
• 診療所
• 外来手術センター（ASCs）

第9章 尿管ステントの世界市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他アジア太平洋地域
• 世界のその他の地域
  • ラテンアメリカ
  • 中東・アフリカ

第10章 世界の尿管ステント市場の競合情勢

• 概要
• 各社の市場ランキング
• 主な発展戦略

第11章 企業プロファイル

• Boston Scientific Corporation
• Coloplast Ltd.
• Allium Medical Solutions Ltd.
• Becton, Dickinson and Company
• Cook Group Incorporated
• Braun Melsungen AG
• R. Bard
• Teleflex Incorporated
• Olympus Corporation
• Biomerics

第12章 主な発展

• 製品の上市／開発
• 合併と買収
• 事業拡大
• パートナーシップと提携

第13章 付録

• 関連調査

Ureteral Stents Market Valuation - 2026-2032

The rising frequency of urological disorders, especially kidney stones, and the use of minimally invasive techniques that improve patient recovery and comfort, are driving the Ureteral Stents Market forward. According to the analyst from Verified Market Research, the Ureteral Stents Market is estimated to reach a valuation of USD 843.74 Million over the forecast subjugating around USD 548.54 Million valued in 2024.

Technological improvements in stent materials and designs, particularly flexible and biocompatible choices, are driving up market demand. It enables the market to grow at a CAGR of 6.1% from 2026 to 2032.

Ureteral Stents Market: Definition/ Overview

A ureteral stent is a thin, flexible tube put into the ureter to aid in the drainage of urine from the kidney to the bladder, especially when normal urine flow is impeded. These stents are widely used to treat kidney stones, ureteral obstructions caused by tumors or strictures, and post-surgical blockages due to swelling or tissue repair. Ureteral stents are an important component in urological therapies because they maintain the ureter open and assist ensure optimal kidney function while also alleviating symptoms associated with urinary obstructions.

What are the Factors that Surge the Demand for the Ureteral Stents Market?

The increased occurrence of kidney stones is a major driver of the Ureteral Stents Market. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) estimates that kidney stones affect approximately 11% of men and 9% of women in the United States. The NIDDK also notes that the incidence of kidney stones in the United States has risen from 3.8% in the late 1970s to 8.8% in the late 2000s. This increasing prevalence needs more ureteral stent surgeries, which drives market expansion.

The global aging population is driving up demand for ureteral stents, as older persons are more prone to urological problems. The World Health Organization (WHO) predicts that by 2030, one in every six persons will be 60 or older. This number is predicted to rise to one in five by 2050. In statistics, this represents a rise from 1 billion in 2020 to 1.4 billion by 2030 and 2.1 billion by 2050. The elderly population is more vulnerable to disorders that necessitate ureteral stents, fueling market expansion.

Furthermore, continuous advancements in ureteral stent design and materials are broadening their uses while improving patient outcomes. For example, the United States Food and Drug Administration (FDA) has been actively approving novel ureteral stent technology. The Newton-Drainer Ureteral Catheter, which is meant to drain stone fragments from the kidney, was designated a Breakthrough Device by the FDA in 2019. Such improvements are expanding the use of ureteral stents and driving market expansion. According to the FDA's Center for Devices and Radiological Health (CDRH), the number of innovative device approvals increased by 25% between 2009 and 2019, demonstrating a trend toward innovation in medical devices, particularly ureteral stents.

What Factors Hinder the Growth of the Ureteral Stents Market?

Drug-eluting and biodegradable stents are examples of breakthroughs that hold out the potential for better outcomes, but their high cost puts patients and healthcare professionals out of reach, especially in areas with few resources. This financial burden discourages the adoption of these sophisticated solutions, resulting in a reliance on less expensive alternatives that do not provide the same benefits.

The risk of problems following the placing of a ureteral stent presents another difficulty. Patients develop complications such as stent migration, encrustation, and urinary tract infections, requiring extra medical treatments. These consequences not only have an impact on patient outcomes but also raise healthcare expenditures and resource use, making doctors hesitant to propose stenting as a first-line treatment option.

Category-Wise Acumens

How Does the Increasing Adoption of Double Pigtail Stents Drive the Market Growth?

According to VMR analysis, the double pigtail stent segment is estimated to hold the largest market share during the forecast period due to its high biocompatibility, which reduces the chance of unpleasant reactions and problems like infection or tissue irritation. This characteristic makes double pigtail stents the favored option among healthcare professionals, resulting in improved patient outcomes and higher satisfaction rates. Their design enables excellent drainage while decreasing the possibility of encrustation, which increases their attractiveness in clinical settings.

Double pigtail stents' flexibility and simplicity of insertion are also significant factors. Their unique form allows for smoother installation using less invasive techniques, making them easier to manage during treatments. This ease of use not only increases procedural efficiency but also reduces patient discomfort, prompting more healthcare practitioners to employ them for a variety of urological procedures.

Furthermore, the increasing prevalence of urological problems, such as kidney stones and urinary tract blockages, is driving demand for double pigtail stents. As these problems become more widespread, particularly in older populations, healthcare providers rely more on these stents to properly address urinary issues. The increasing prevalence of such illnesses confirms the market dominance of double pigtail stents, which are best adapted to resolving these issues.

How Does the High Prevalence of Kidney Stones Propel the Growth of the Ureteral Stents Market?

The kidney stone segment is estimated to dominate the Ureteral Stents Market during the forecast period due to the high occurrence of kidney stones. Kidney stones impact a large proportion of the global population, creating a growing demand for effective treatment alternatives. Ureteral stents are frequently utilized to relieve obstruction produced by these stones, maintaining correct urine flow and minimizing accompanying pain, emphasizing their critical role in addressing this problem.

Technological developments in stent design are also important for segment growth. Drug-eluting and biodegradable stents are examples of innovations that improve kidney stone treatment effectiveness, patient outcomes, and comfort. These developments not only make it easier to pass stones, but they also reduce complications, leading healthcare practitioners to select ureteral stents as the preferred technique for managing kidney stones.

Furthermore, the growing knowledge and accessibility of healthcare services help to drive the growth of the kidney stones segment. As more patients seek medical assistance for urological disorders, understanding of kidney stone management has grown. This trend promotes timely treatments with ureteral stents, consolidating their position as the preferred method for treating kidney stone-related blockages.

Country/Region-wise Acumens

How Does the High Prevalence of Urological Disorders Influence Growth in North America?

According to VMR analyst, North America is estimated to dominate the Ureteral Stents Market during the forecast period. Urological problems are common in North America, especially in the United States, and are frequently treated using ureteral stents. According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), around 11% of men and 6% of women in the United States will have kidney stones at some point in their life. Also, the American Urological Association says that benign prostatic hyperplasia (BPH) affects approximately 50% of men aged 51 to 60 and up to 90% of men over the age of 80, with many requiring ureteral stents as part of their treatment.

Furthermore, the expanding geriatric population in North America is a significant driver of the Ureteral Stents Market, as older persons are more prone to urological problems. According to the United States Census Bureau, by 2030, all baby boomers will be above the age of 65, increasing the number of the elderly population to one in every five individuals. Specifically, the number of Americans aged 65 and over is expected to increase from 52 million in 2018 to 95 million by 2060. This demographic trend is projected to boost demand for urological procedures, such as ureteral stents.

What Factors Contribute to the Potential Opportunities in the Asia Pacific Region?

The Asia Pacific region is estimated to exhibit the highest growth within the Ureteral Stents Market during the forecast period. The Asia Pacific region is experiencing considerable growth in the older population, which is particularly vulnerable to urological illnesses that require ureteral stents. According to the United Nations Economic and Social Commission for Asia and the Pacific (UNESCAP), the region's elder population (aged 65 and more) is predicted to more than double from 535 million in 2015 to around 1.3 billion by 2050. In countries such as Japan, the proportion of people aged 65 and more is expected to reach 38% by 2050. This demographic trend is expected to increase demand for ureteral stents and other urological treatments.

Furthermore, the Asia Pacific region is experiencing an increase in urological problems, particularly kidney stones. According to research published in the Asian Journal of Urology, the prevalence of kidney stone illness in China has risen from 4% in the 1980s to 6.4% in the 2000s. According to India's Department of Health & Family Welfare's Annual Report 2020-2021, urolithiasis (kidney stones) is growing more common, with a prevalence rate of 12% in the adult population. This increased disease burden is likely to drive up demand for ureteral stents in the region.

Competitive Landscape

The Ureteral Stents Market has a broad set of participants, including both large global organizations and smaller, specialized firms. This fragmentation encourages innovation, as businesses focus more on developing new stent technologies, such as drug-eluting and biodegradable choices, to improve patient outcomes and satisfaction.

Some of the prominent players operating in the Ureteral Stents Market include:

Boston Scientific Corporation, Coloplast Ltd., Allium Medical Solutions Ltd., Becton, Dickinson and Company, Cook Group Incorporated, Braun Melsungen AG, Bard, Teleflex Incorporated, Olympus Corporation, and Biomerics.

Latest Developments

In May 2022, University Hospitals invented a novel stent developed by Ureteral Stent Co. Lee Ponsky, MD, and obtained FDA Clearance. Ureteral stents facilitate urine flow from the kidney to the bladder, preventing kidney damage caused by kidney stones, strictures, or ureter edema.

In April 2022, Boston Scientific received a bronze Edison Award in the Science & Medical category for its Tria Ureteral Stent. This stent is the first to use proprietary surface technology to prevent the accumulation of calcium and magnesium salt deposits in urine.

Ureteral Stents Market, By Category

• Product:
• Open End Stents
• Double J-Stents
• Closed End Stents
• Multiloop Stents
• Material:
• Metallic Stents
• Polymer Stents
• Application:
• Kidney Stones
• Kidney Transplantation
• Tumors
• Urinary Incontinence
• Others
• End-User:
• Hospitals
• Clinics
• Ambulatory Surgical Centers (ASCs)
• Region:
• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL URETERAL STENTS MARKET

• 1.1 Introduction of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL URETERAL STENTS MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL URETERAL STENTS MARKET, BY PRODUCT

• 5.1 Overview
• 5.2 Open End Stents
• 5.3 Double J-Stents
• 5.4 Closed End Stents
• 5.5 Multiloop Stents

6 GLOBAL URETERAL STENTS MARKET, BY MATERIAL

• 6.1 Overview
• 6.2 Metallic Stents
• 6.3 Polymer Stents

7 GLOBAL URETERAL STENTS MARKET, BY APPLICATION

• 7.1 Overview
• 7.2 Kidney Stones
• 7.3 Kidney Transplantation
• 7.4 Tumors
• 7.5 Urinary Incontinence
• 7.6 Others

8 GLOBAL URETERAL STENTS MARKET, BY END-USER

• 8.1 Overview
• 8.2 Hospitals
• 8.3 Clinics
• 8.4 Ambulatory Surgical Centers (ASCs)

9 GLOBAL URETERAL STENTS MARKET, BY GEOGRAPHY

• 9.1 Overview
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 U.K.
  • 9.3.3 France
  • 9.3.4 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Rest of Asia Pacific
• 9.5 Rest of the World
  • 9.5.1 Latin America
  • 9.5.2 Middle East and Africa

10 GLOBAL URETERAL STENTS MARKET COMPETITIVE LANDSCAPE

• 10.1 Overview
• 10.2 Company Market Ranking
• 10.3 Key Development Strategies

11 COMPANY PROFILES

• 11.1 Boston Scientific Corporation
  • 11.1.1 Overview
  • 11.1.2 Financial Performance
  • 11.1.3 Product Outlook
  • 11.1.4 Key Developments
• 11.2 Coloplast Ltd.
  • 11.2.1 Overview
  • 11.2.2 Financial Performance
  • 11.2.3 Product Outlook
  • 11.2.4 Key Developments
• 11.3 Allium Medical Solutions Ltd.
  • 11.3.1 Overview
  • 11.3.2 Financial Performance
  • 11.3.3 Product Outlook
  • 11.3.4 Key Developments
• 11.4 Becton, Dickinson and Company
  • 11.4.1 Overview
  • 11.4.2 Financial Performance
  • 11.4.3 Product Outlook
  • 11.4.4 Key Developments
• 11.5 Cook Group Incorporated
  • 11.5.1 Overview
  • 11.5.2 Financial Performance
  • 11.5.3 Product Outlook
  • 11.5.4 Key Developments
• 11.6 Braun Melsungen AG
  • 11.6.1 Overview
  • 11.6.2 Financial Performance
  • 11.6.3 Product Outlook
  • 11.6.4 Key Developments
• 11.7 R. Bard
  • 11.7.1 Overview
  • 11.7.2 Financial Performance
  • 11.7.3 Product Outlook
  • 11.7.4 Key Developments
• 11.8 Teleflex Incorporated
  • 11.8.1 Overview
  • 11.8.2 Financial Performance
  • 11.8.3 Product Outlook
  • 11.8.4 Key Developments
• 11.9 Olympus Corporation
  • 11.9.1 Overview
  • 11.9.2 Financial Performance
  • 11.9.3 Product Outlook
  • 11.9.4 Key Developments
• 11.10 Biomerics
  • 11.10.1 Overview
  • 11.10.2 Financial Performance
  • 11.10.3 Product Outlook
  • 11.10.4 Key Developments

12 KEY DEVELOPMENTS

• 12.1 Product Launches/Developments
• 12.2 Mergers and Acquisitions
• 12.3 Business Expansions
• 12.4 Partnerships and Collaborations

13 Appendix

• 13.1 Related Research